Evidence map›Paper›PMID 27974388›Full record

ArticleClinical chemistry2017

Monitoring Glycemic Control in End-Stage Renal Disease: What Should Be Measured?

Elizabeth Selvin, David B Sacks

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Observational
  2. Diabetes and Glucose Management in People on Hemodialysis.Diabetes spectrum : a publication of the American Diabetes Association · 2025
    Article
  3. Glycated Albumin and Adverse Clinical Outcomes in Patients With CKD: A Prospective Cohort Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Update on biomarkers of glycemic control.World journal of diabetes · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Elizabeth SelvinDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
David B SacksDepartment of Laboratory Medicine, NIH, Bethesda, MD. sacksdb@mail.nih.gov.

Funding

Diabetes and Prediabetes in Older Adults in ARICR01DK089174 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SELVIN, ELIZABETH · 2011 to 2020
$6.4M
Alternative Biomarkers of Hyperglycemia in ADVANCER01DK108784 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SELVIN, ELIZABETH · 2016 to 2019
$2.0M
Research and Mentoring in the Clinical Epidemiology of Type 2 DiabetesK24DK106414 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SELVIN, ELIZABETH · 2015 to 2019
$654k
NIDDK NIH HHS K24 DK106414NIDDK NIH HHS R01 DK089174NIDDK NIH HHS R01 DK108784
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Kidney Failure, ChronicBlood GlucoseGlycated Serum AlbuminGlycation End Products, AdvancedHumansRenal DialysisSerum AlbuminBlood GlucoseGlycated Serum AlbuminGlycation End Products, AdvancedSerum Albumin

Identifiers

PMID27974388
PMCPMC5337943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.